Some aspects of the endocrine profile and management of hormone-dependent male breast cancer

Oncologist

Volumn 12, Issue 7, 2007, Pages 798-807

  Dimitrov, Nikolay V ^a   Colucci, Philomena ^a   Nagpal, Sunil ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Endocrine; Hormone; Male breast cancer

Indexed keywords

ANASTROZOLE; ANDROSTENEDIONE; ANTHRACYCLINE; ANTIANDROGEN; AROMATASE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FOLLITROPIN; FULVESTRANT; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; HORMONE RECEPTOR; LUTEINIZING HORMONE; PROGESTERONE RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STERYL SULFATASE; TAMOXIFEN; TESTOSTERONE;

ADVANCED CANCER; AROMATIZATION; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGISTRY; CANCER SURVIVAL; CELL STRAIN MCF 7; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ACTIVITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE SURGERY; ENZYME INHIBITION; ESTROGEN METABOLISM; ESTROGEN RELEASE; ESTROGEN SYNTHESIS; ESTROGEN URINE LEVEL; GASTROINTESTINAL DISEASE; GENE EXPRESSION; HORMONE SYNTHESIS; HOT FLUSH; HUMAN; IMPOTENCE; LEYDIG CELL; LIBIDO DISORDER; MALE BREAST; MEDICAL RECORD REVIEW; MONOTHERAPY; NONHUMAN; NUDE MOUSE; ORCHIECTOMY; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; OVARY FUNCTION; PATIENT CARE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS, MALE; ENDOCRINE GLANDS; ESTROGENS; FEMALE; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TESTOSTERONE;

EID: 34548269549     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-7-798     Document Type: Review

References (88)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-130.
2. Amir H, Makwaya CK, Moshiro C et al. Carcinoma of the male breast: A sexually transmitted disease? East Afr Med J 1996;73:187-190.
3. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538-549.
4. La Vecchia C, Levi F, Lucchini F. Descriptive epidemiology of male breast cancer in Europe. Int J Cancer 1992;51:62-66.
5. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678-687.
6. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Available at http://seer.cancer.gov/csr/1975_2004results_ merged/sect_04_breast.pdf. Accessed June 9, 2007.
7. Donegan WL, Redlich PN, Lang PJ et al. Carcinoma of the breast in males: A multiinstitutional survey. Cancer 1998;83:498-509.
8. Jaiyesimi IA, Buzdar AU, Sahin AA et al. Carcinoma of the male breast. Ann Intern Med 1992;117:771-777.
9. Giordano SH. A review of the diagnosis and management of male breast cancer. The Oncologist 2005;10:471-479.
10. Anderson WF, Althuis MD, Brinton LA et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83:77-86.
11. Meyskens FL Jr, Tormey DC, Neifeld JP. Male breast cancer: A review. Cancer Treat Rev 1976;3:83-93.
12. Nahleh ZA. Hormonal therapy for male breast cancer: A different approach for a different disease. Cancer Treat Rev 2006;32(:101-105.
13. Giordano SH, Cohen DS, Buzdar AU et al. Breast carcinoma in men: A population-based study. Cancer 2004;101:51-57.
14. Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ breast cancer incidence: A possible explanation (United States). Cancer Causes Control 2002;13:7-14.
15. Murphy CE, Carder PJ, Lansdown MR et al. Steroid hormone receptor expression in male breast cancer. Eur J Surg Oncol 2006;32:44-47.
16. Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 1962;18:387-414.
17. Jensen EV, Block GE, Smith S et al. Estrogen receptors and breast cancer response to adrenalectomy. Natl Cancer Inst Monogr 1971;34:55-70.
18. Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 1996;32A:1686-1692.
19. Gruvberger-Saal SK, Bendahl PO, Saal LH et al. Estrogen receptor-beta has favorable independent prognostic value for estrogen-alpha negative breast cancer patients receiving adjuvant tamoxifen. Presented at the 2006 American Society of Clinical Oncology Annual Meeting, Atlanta, GA, June 2-6, 2006.
20. Stendahl M, Ryden L, Nordenskjold B et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients. Clin Cancer Res 2006;12:4614-4618.
21. Arpino G, Weiss H, Lee AV et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-1261.
22. Dowsett M, Allred DC, on behalf of the TransATAC Investigators. Relationship between quantitative ER and PgR expression and HER-2 status with recurrence in ATAC trial. Presented at the 2006 San Antonio Breast Cancer Symposium, San Antonio, TX, December 17, 2006.
23. Lippman ME, Bolan G. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 1975;256:592-593.
24. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351:1451-1467.
25. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
26. Jordan VC, Knudson AG. Improvements in tumor targeting, survivorship, and chemoprevention pioneered by tamoxifen. A personal perspective. Oncology (Williston Park) 2006;20:553-562; discussion 567-568, 573, 577.
27. Goss PE, Reid C, Pintilie M et al. Male breast carcinoma: A review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955-1996. Cancer 1999;85:629-639.
28. Wang-Rodriguez J, Cross K, Gallagher S et al. Male breast carcinoma: Correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002;15:853-861.
29. Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:20-26.
30. Young IE, Kurian KM, Mackenzie MA et al. The CAG repeat within the androgen receptor gene in male breast cancer patients. J Med Genet 2000;37:139-140.
31. Menin C, Banna GL, De Salvo G et al. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett 2001;168:31-36.
32. Crichlow RW. Carcinoma of the male breast. Surg Gynecol Obstet 1972;134:1011-1019.
33. Zumoff B, Fishman J, Cassouto J et al. Estradiol transformation in men with breast cancer. J Clin Endocrinol Metab 1966;26:960-966.
34. Fishman LM, Sarfaty GA, Wilson H et al. The role of the testis in oestrogen production. Ciba Found Collo Qendocrinol 1967;16:156.
35. Longcope C, Kato T, Horton R. Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest 1969;48:2191-2201.
36. MacDonald PC, Madden JD, Brenner PF et al. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979;49:905-916.
37. Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975;86:212-215.
38. Hsing AW, McLaughlin JK, Cocco P et al. Risk factors for male breast cancer (United States). Cancer Causes Control 1998;9:269-275.
39. Scheike O. Factors provoking male breast cancer. In: Stoll BS, ed. Risk Factors in Breast Cancer. London: Heinemann Medical Books, Ltd., 1976: 173-177.
40. Federman DD. The biology of human sex differences. N Engl J Med 2006;354:1507-1514.
41. Giordano SH, Valero V, Buzdar AU et al. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235-237.
42. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: A case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005;90:26-30.
43. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
44. Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-1667.
45. Stewart PM. Aging and fountain-of-youth hormones. N Engl J Med 2006;355:1724-1726.
46. Dao TL, Morreal C, Nemoto T. Urinary estrogen excretion in men with breast cancer. N Engl J Med 1973;289:138-140.
47. Calabresi E, De Giuli G, Becciolini A et al. Plasma estrogens and androgens in male breast cancer. J Steroid Biochem 1976;7:605-609.
48. Treves N. The treatment of cancer, especially inoperable cancer, of the male breast by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids); an analysis of 42 patients. Cancer 1959;12:820-832.
49. Vorobiof DA, Falkson G. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 1987;59:688-689.
50. Lopez M. Cyproterone acetate in the treatment of metastatic cancer of the male breast. Cancer 1985;55:2334-2336.
51. Mitsuyasu R, Bonomi P, Anderson K et al. Response to megestrol in male breast carcinoma. Arch Intern Med 1981;141:809-810.
52. Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 1984;53:1344-1346.
53. Kantarjian H, Yap HY, Hortobagyi G et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983;143:237-240.
54. Neifeld JP, Meyskens F, Tormey DC et al. The role of orchiectomy in the management of advanced male breast cancer. Cancer 1976;37:992-995.
55. Kraybill WG, Kaufman R, Kinne D. Treatment of advanced male breast cancer. Cancer 1981;47:2185-2189.
56. Li MC, Janelli DE, Kelly EJ et al. Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy. Cancer 1970;25:678-681.
57. Becher R, Hoffken K, Pape H et al. Tamoxifen treatment before orchiectomy in advanced breast cancer in men. N Engl J Med 1981;305:169-170.
58. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: A 13-year review of 89 patients. J Clin Oncol 1984;2:903-909.
59. Ikkos D, Ljunggren H, Luft R et al. Hypophysectomy in the treatment of malignant tumors. Am J Med 1956;21:728-738.
60. Stephens RL, Muggia FM. Breast cancer in men. Report illustrating the value of endocrine ablation. Am J Med 1974;57:679-682.
61. Ribeiro GG. Tamoxifen in the treatment of male breast carcinoma. Clin Radiol 1983;34:625-628.
62. Lopez M, Di Lauro L, Lazzaro B et al. Hormonal treatment of disseminated male breast cancer. Oncology 1985;42:345-349.
63. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992;65:252-254.
64. Anelli TF, Anelli A, Tran KN et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994;74:74-77.
65. Giordano SH, Perkins GH, Broglio K et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005;104:2359-2364.
66. Patterson JS, Battersby LA, Bach BK. Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 1980;64:801-804.
67. Osborne CK, Pippen J, Jones SE et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20:3386-3395.
68. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-750.
69. Bundred N. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest 2005;23:173-181.
70. Gradishar WJ, Sahmoud T. Current and future perspectives on fulvestrant. Clin Breast Cancer 2005;6(suppl 1):S23-S29.
71. Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007;101:123.
72. Baum M, Buzdar A, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-1810.
73. Vermeulen A. Andropause. Maturitas 2000;34:5-15.
74. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24:e42-e43.
75. Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988;62:474-478.
76. Hirbe A, Morgan EA, Uluckan O et al. Skeletal complications of breast cancer therapies. Clin Cancer Res 2006;12:6309s-6314s.
77. Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-935.
78. Santen R, Jeng MH, Wang JP et al. Adaptive hypersensitivity to estradiol: Potential mechanism for secondary hormonal responses in breast cancer patients. J Steroid Biochem Mol Biol 2001;79:115-125.
79. Schiff R, Massarweh SA, Shou J et al. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331S-336S.
80. Storniolo AM, Burris H, Pegram M et al. A phase I open-label study of lapatinib (GW 572016) plus trastuzumab: A clinically active regimen. J Clin Oncol ASCO Annual Meeting Proceedings 2005; 23(suppl 16S):559.
81. Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation-and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18-25.
82. Syrjakoski K, Hyytinen ER, Kuukasjarvi T et al. Androgen receptor gene alterations in Finnish male breast cancer. Breast Cancer Res Treat 2003;77:167-170.
83. Rudlowski C, Friedrichs N, Faridi A et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84:215-223.
84. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
85. Feigelson HS, Shames LS, Pike MC et al. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-587.
86. Young IE, Kurian KM, Annink C et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 1999;81:141-143.
87. Dunning AM, Healey CS, Pharoah PD et al. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 1998;77:2045-2047.
88. O'Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N Engl J Med 2006;355:615-617.